CRMD

CorMedix Inc.

$5.37

-1.83%
SectorHealthcareIndustryBiotechnologyCountryUnited States

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

Source: Yahoo Finance
AI summary

Price & performance

1M-26.0%
3M-24.0%
YTD-53.2%
1Y-51.0%
52-week range—
Beta1.03
Full chart and returns against a benchmark

Q-Score

87/ 100

Quality against peers; 50 is the peer median.

Growth76
Risk58
Performance58
Valuation96
Profitability79
Leverage67
Sentiment40
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$311.7M+617.0%
Net income$163.1M
Net margin52.3%+93.6 pts
Historical fundamentals

Red flags in filings

2active red flags
Material weakness in controlsMar 5, 2026
Auditor changeJul 1, 2026
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Largest customer38%
Regions, segments, customers and suppliers

Valuation

CRMDIndustryP/E2.2889.69P/S0.9211.88EV/EBITDA0.7167.10P/B0.936.22PEG0.014.02
Dividend yield0.00%
Every valuation metric

Earnings

Nov 12next report, before the open
EPS estimate—
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate